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p25/Cdk5 dysregulation may contribute to neurodegeneration. In this issue of Neuron, Kim et al. show that
cdk5 inactivates HDAC-1, leading to cell cycle deregulation and DNA damage accumulation. This study
provides further insights into the function of p25/Cdk5 in neurons and points to HDAC-1 as a target for
therapeutic interventions.Neurodegenerative and cerebrovascular
disorders are among the most common
neurological diseases. Significant prog-
ress has been made toward gaining in-
sights into the causes of many of these
prevalent illnesses, but the nature of the
mechanisms by which neurons die under
these pathological conditions remains
poorly understood. In search of such mo-
lecular clues, many scientists now believe
that abnormal kinase signaling, especially
involving the proline-directed serine/thre-
onine protein kinase, cyclin-dependent
kinase 5 (Cdk5), might be an important
piece of the puzzle.
Cdk5 is ubiquitously expressed in neu-
rons, but the associated kinase activity is
tightly controlled by its major non-cyclin
activator p35 (Dhavan and Tsai, 2001).
Several lines of evidence indicate that
Cdk5 contributes to normal brain devel-
opment where it plays a role in axon guid-
ance and neuronal migration (Dhavan and
Tsai, 2001). Cdk5, through the phosphor-
ylation of a broad range of pre- and post-
synaptic proteins, also regulates neuro-
transmission and synaptic plasticity, and
thus, plays an important role in cognitive
functions such as learning and memory
(Cheung et al., 2006; Fischer et al.,
2005). Cdk5 may also modulate locomo-
tor responses to cocaine (Meyer et al.,
2008). The above examples illustrate the
broad range of Cdk5 functions in the ner-
vous system.
Furthermore, aberrant Cdk5 signaling
has been proposed to be a common con-
tributor to a variety of CNS disorders
(Cruz and Tsai, 2004; Nguyen et al., 2003;
Qu et al., 2007; Rashidian et al., 2005).
Cdk5 deregulation is presumably the con-
sequence of a neuronal accumulation of
p25, a C-terminal fragment of p35 gener-ated by the Ca2+-dependent proteases
calpains (Lee et al., 2000). While p25 en-
compasses the minimal region required
for Cdk5 binding and activation, it lacks
the p35 N-terminal myristoylation signal
and, unlike p35, it is not readily degraded
by the proteasome system (Dhavan and
Tsai, 2001).Consequently,p25/Cdk5com-
plex is not properly targeted to the plasma
membrane and Cdk5 is hyperactivated.
To determine whether the generation
and accumulation of p25 followed by al-
terations in Cdk5 signaling can indeed
cause neuronal death, bitransgenic mice
were created to have an inducible expres-
sion of GFP-tagged human p25 in
forebrain neurons (Cruz et al., 2003).
Research on these mice has been quite
enlightening in that, upon postnatal doxy-
cycline withdrawal, not only do these ani-
mals show high forebrain p25 levels and
Cdk5 activity, they also develop cognitive
deficits, brain atrophy, and overt hippo-
campal neuronal loss and gliosis (Cruz
et al., 2003; Fischer et al., 2005). How-
ever, these studies have not shed light
on the precise molecular mechanisms
by which p25/Cdk5 mediate neuronal
death. In this issue of Neuron, Kim and
collaborators (Kim et al., 2008) identify
a novel and exciting mechanistic link
between aberrant p25/Cdk5 signaling,
histone deacetylases (HDACs), and neu-
rodegeneration.
Kim and colleagues began their search
for the missing link between p25/Cdk5
and neuronal death by screening for early
transcriptional differences in adult p25 in-
duced transgenic mice and noninduced
controls. By microarray profiling, Kim
et al. found that 1/3 of the differentially
regulated genes encoded for either cell
cycle factors or DNA damage/repairNeuron 60,response proteins. The authors hypothe-
sized that an increase in histone acetyla-
tion due to reduced HDAC activity,
through its effects on chromatin remodel-
ing and transcriptional regulation, may
well be the culprit. Among the large num-
ber of HDAC isoforms, Kim et al. likely
focused on HDAC1, because its inhibition
is associated with transcriptional alter-
ations (Peart et al., 2005) and because
HDAC1 plays an essential and nonredun-
dant role in development and cell survival
(Lagger et al., 2002).
Previous studies have found that many
molecules that interact with Cdk5 also
bind to p35 and p25. The authors found
that a region in the N-terminal region of
HDAC1, within its histone deacetylase
catalytic domain, bound directly to p25
and that this interaction impaired HDAC1
functions. Inactivation of HDAC1 led to
an aberrant expression of cell cycle pro-
teins and an accumulation of DNA dam-
age, ultimately provoking cell death via
apoptosis, similar to the pathology seen
after transient cerebral ischemic events.
Strikingly, the authors found that somatic
overexpression of wild-type HDAC1 at-
tenuated this ischemic-related pathologic
phenotype.
While these results support the potential
benefit of promoting HDAC1 activity to
fight against ischemic-related neurode-
generation, further studies will be needed
to decipher the precise nature of this
Cdk5-dependent effect on HDAC1. From
a preclinical standpoint, additional insight
could have been gained if the authors had
assessed the effects of targeting HDAC1
activity, not only before, but also after
the ischemic accident, to better emulate
the situation encountered in patients.
Nonetheless, the results are an importantDecember 11, 2008 ª2008 Elsevier Inc. 731
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ies. In contrast to the data
presented here, preclinical
studies using either pan- or
class-specific-HDAC antago-
nists have shown that inhibi-
tion, and not stimulation of
protein deacetylation, was
protective against neurode-
generation inmodels of motor
neuron or polyglutamine-
repeat diseases (Kazantsev
and Thompson, 2008). Could
these contradicting results
reflect disease pathways in-
volving specifically different
HDAC isoforms? Interest-
ingly, the HDAC1 binding
domain with p25 share 90%
sequence homology with
HDAC2 and 50% with
HDAC3. Thus, it may also be
informative to know whether
p25 binds to and affects the
activity of these distinct
class-I HDAC isoforms, par-
ticularly since they may have




Kim and collaborators pro-
vide a tantalizing new sce-
nario for p25/Cdk5-mediated
neurodegeneration articu-
lated around HDAC1 inacti-
vation and an ensuing inappropriate
reactivation of the cell cycle and an
accumulation of DNA damage, but sev-
eral additional p25/Cdk5-related patho-
genic scenarios have been characterized
(Figure 1). For instance, it has also been
proposed that p25/Cdk5 deleterious ef-
fects could result from the hyperphos-
phorylation of tau and other neuronal sub-
strates (Cruz and Tsai, 2004; Nguyen
et al., 2003), increased NMDA receptor
channel activity (Wang et al., 2003), inhibi-
tion of peroxiredoxin-2 (Qu et al., 2007), or
even induction of b-secretase (Wen et al.,
2008). Since these observations were
made in different disease models, it is
possible that p25/Cdk5 recruits distinct
deleterious cascades, depending on the
initiating event (e.g., ischemia versus neu-
rotoxin) or the type of neurons affected
(e.g., cholinergic versus dopaminergic).
Alternatively, these mechanisms are not
necessarily mutually exclusive and there-
fore, the most parsimonious explanation
would be to consider that most, if not all,
of these mechanisms may be effectors
of aberrant p25/Cdk5 activation and con-
tribute to the neurodegenerative process.
If correct, this view will have far-reaching
implications to both our understanding
of the function of p25/Cdk5 and the neu-
robiology of a range of disease mecha-
nisms. Indeed, this work firmly places
p25/Cdk5 at the crossroads toward which
many disease-initiating factors converge
and from which many cell death effectors
depart.
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Figure 1. Unifying Pathogenic Scenario for Aberrant p25/Cdk5-
Mediated Neurodegeneration
Abnormal production of p25 and activation of Cdk5 may be linked to Parkin-
son’s disease (PD), amyotrophic lateral sclerosis (ALS), ischemia, and Alz-
heimer’s disease (AD). The role of p25/Cdk5 in each of these different condi-
tions has been related to unique signaling events as indicated. Collectively,
these cellular perturbations culminate in the demise of the affected cells, likely
by apoptosis.732 Neuron 60, December 11, 2008 ª2008 Elsevier Inc.
